Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hepatitis A vaccine is a biologic preparation used to provide active immunity against the hepatitis A virus (HAV). Most globally available formulations consist of whole-cell inactivated virus (such as the HM175 strain), although live attenuated versions are utilized in specific regions like China. The vaccine is typically administered as a two-dose series via intramuscular injection and is highly effective at preventing infection and subsequent liver disease. It is recommended for routine pediatric immunization, travelers to endemic areas, and individuals with chronic liver disease or other high-risk factors. Major developers and manufacturers include GSK, Merck, and Sanofi.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hepatitis A vaccine.